Literature DB >> 31996792

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Alexandros Spyridonidis1, Myriam Labopin2, Bipin N Savani3, Riitta Niittyvuopio4, Didier Blaise5, Charles Craddock6, Gerard Socié7, Uwe Platzbecker8, Dietrich Beelen9, Noel Milpied10, Jan J Cornelissen11, Arnold Ganser12, Anne Huynh13, Laimonas Griskevicius14, Sebastian Giebel15, Mahmoud Aljurf16, Eolia Brissot2, Florent Malard2, Jordi Esteve17, Zinaida Peric18, Frédéric Baron19, Annalisa Ruggeri20, Christoph Schmid21, Maria Gilleece22, Norbert-Claude Gorin2, Francesco Lanza23, Roni Shouval24, Jurjen Versluis12, Gesine Bug25, Yngvar Fløisand26, Fabio Ciceri27, Jamie Sanz28, Ali Bazarbachi29, Arnon Nagler30, Mohamad Mohty2.   

Abstract

To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell transplantation (HCT). We assigned intensity weight scores for frequently used conditioning regimen components and used their sum to generate the transplant conditioning intensity (TCI) score. We retrospectively tested the impact of TCI on 8255 adult (45-65 years) acute myeloid leukemia patients who underwent HCT in first complete remission. A Cox model for early nonrelapse mortality (NRM) yielded a 3-group TCI risk scheme (low, intermediate, high) with respective TCI scores of [1-2], [2.5-3.5] and [4-6]. On multivariate modeling, TCI grouping was highly and better predictive for early (day 100 and 180) NRM, 2-year NRM and relapse (REL) as compared with the RIC/MAC classification. Validation was done on 200 bootstrap samples. Moreover, TCI scoring enabled the identification of a distinct subgroup of RIC and MAC conditioning regimens with an intermediate TCI [2.5-3.5] score that had identical outcomes and which are frequently referred as "reduced toxicity conditioning". TCI scheme provides an improvement of the RIC/MAC classification. We propose TCI as a new tool to define and measure the conditioning regimen intensity.

Entities:  

Mesh:

Year:  2020        PMID: 31996792     DOI: 10.1038/s41409-020-0803-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  25 in total

1.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Christoph Schmid; Michael Schleuning; Georg Ledderose; Johanna Tischer; Hans-Jochem Kolb
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up.

Authors:  A Bacigalupo; A M Raiola; T Lamparelli; F Gualandi; D Occhini; S Bregante; A Ibatici; C di Grazia; A Dominietto; B Bruno; M T Van Lint; F Frassoni
Journal:  Bone Marrow Transplant       Date:  2007-10-01       Impact factor: 5.483

3.  Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Authors:  J B Langenhorst; C van Kesteren; E M van Maarseveen; T P C Dorlo; S Nierkens; C A Lindemans; M A de Witte; A van Rhenen; R Raijmakers; M Bierings; J Kuball; A D R Huitema; J J Boelens
Journal:  Blood Adv       Date:  2019-07-23

Review 4.  Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.

Authors:  Salyka Sengsayadeth; Bipin N Savani; Didier Blaise; Florent Malard; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

5.  Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.

Authors:  Reinhard Marks; Karin Potthoff; Joachim Hahn; Gabriele Ihorst; Hartmut Bertz; Alexandros Spyridonidis; Ernst Holler; Jürgen M Finke
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

6.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

7.  Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus.

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2004-04       Impact factor: 5.483

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 9.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Authors:  Boglarka Gyurkocza; Brenda M Sandmaier
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

10.  Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

Authors:  Avichai Shimoni; Myriam Labopin; Bipin Savani; Rose-Marie Hamladji; Dietrich Beelen; Ghulam Mufti; Gerard Socié; Jeremy Delage; Didier Blaise; Patrice Chevallier; Edouard Forcade; Eric Deconinck; Mohamad Mohty; Arnon Nagler
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-13       Impact factor: 5.742

View more
  16 in total

1.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

2.  Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).

Authors:  Eleni Gavriilaki; Myriam Labopin; Ioanna Sakellari; Urpu Salmenniemi; Ibrahim Yakoub-Agha; Victoria Potter; Ana Berceanu; Alessandro Rambaldi; Inken Hilgendorf; Nicolaus Kröger; Stephan Mielke; Tsila Zuckerman; Jaime Sanz; Alessandro Busca; Hakan Ozdogu; Achilles Anagnostopoulos; Bipin Savani; Sebastian Giebel; Ali Bazarbachi; Alexandros Spyridonidis; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2022-09-22       Impact factor: 5.174

3.  A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT.

Authors:  Henning Schäfer; Jacqueline Blümel-Lehmann; Gabriele Ihorst; Hartmut Bertz; Ralph Wäsch; Robert Zeiser; Jürgen Finke; Reinhard Marks
Journal:  Ann Hematol       Date:  2021-03-23       Impact factor: 3.673

4.  Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.

Authors:  Jochen J Frietsch; Jenny Miethke; Paul Linke; Carl C Crodel; Ulf Schnetzke; Sebastian Scholl; Andreas Hochhaus; Inken Hilgendorf
Journal:  Bone Marrow Transplant       Date:  2022-05-10       Impact factor: 5.174

5.  Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Authors:  Xavier Roussel; Etienne Daguindau; Ana Berceanu; Yohan Desbrosses; Walid Warda; Mathieu Neto da Rocha; Rim Trad; Eric Deconinck; Marina Deschamps; Christophe Ferrand
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

Review 6.  Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently.

Authors:  Francesco Saraceni; Ilaria Scortechini; Alessandro Fiorentini; Maria Vittoria Dubbini; Giorgia Mancini; Irene Federici; Francesca Romana Colaneri; Antonio Federico Lotito; Selene Guerzoni; Bruna Puglisi; Attilio Olivieri
Journal:  Clin Hematol Int       Date:  2021-08-19

7.  The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.

Authors:  Roni Shouval; Joshua A Fein; Christina Cho; Scott T Avecilla; Josel Ruiz; Ana Alarcon Tomas; Miriam Sanchez-Escamilla; Nerea Castillo Flores; Lucrecia Yáñez; Juliet N Barker; Parastoo Dahi; Sergio A Giralt; Alexander I Geyer; Boglarka Gyurkocza; Ann A Jakubowski; Richard J Lin; Richard J O'Reilly; Esperanza B Papadopoulos; Ioannis Politikos; Doris M Ponce; Craig S Sauter; Michael Scordo; Brian Shaffer; Gunjan L Shah; James P Sullivan; Roni Tamari; Marcel R M van den Brink; James W Young; Arnon Nagler; Sean Devlin; Avichai Shimoni; Miguel-Angel Perales
Journal:  Blood Adv       Date:  2022-03-08

Review 8.  Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans.

Authors:  Robert Lowsky; Samuel Strober
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

9.  Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Francesco Saraceni; Myriam Labopin; Edouard Forcade; Nicolaus Kröger; Gerard Socié; Riitta Niittyvuopio; Jan J Cornelissen; Hélène Labussière-Wallet; Didier Blaise; Goda Choi; Jenny L Byrne; Gaelle Guillerm; Tony Marchand; Jordi Esteve; Ali Bazarbachi; Bipin Savani; Attilio Olivieri; Arnon Nagler; Mohamad Mohty
Journal:  Cancer Med       Date:  2020-11-26       Impact factor: 4.452

10.  Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors.

Authors:  Maciej Majcherek; Agnieszka Matkowska-Kocjan; Donata Szymczak; Magdalena Karasek; Agnieszka Szeremet; Aleksandra Kiraga; Aneta Milanowska; Edwin Kuznik; Krzysztof Kujawa; Tomasz Wrobel; Leszek Szenborn; Anna Czyz
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.